Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients

It has been previously documented that some antipsychotic medications could deteriorate the protective efficacy of vaccines. Likewise, we have initially observed that a significantly increased number of schizophrenic inpatients became ill irrespective of COVID-19 vaccination compared to healthy hospital workers. Thus, we examined the effects of anti-psychiatric medication on the COVID-19 incidence. A cohort study was conducted with 98 schizophrenia inpatients and 78 control hospital staff members, all of whom received the COVID-19 vaccine between July and September 2021. COVID-19 incidence and vaccine-related side effects were compared between these two groups. The schizophrenia group had a significantly higher incidence of COVID-19 (40.8%) compared to the control group (12.8%) (P < 0.01). In particular, risperidone monotherapy was associated with a significant increase in COVID-19 incidence (65.6%), whereas aripiprazole use was linked to a significant reduction (0%) (P < 0.01). No such difference in COVID-19 incidence was observed in patients using olanzapine. Risperidone administration appears to impair the immune responses and reduce vaccine effectiveness. Further studies with extended subjects and other vaccines are warranted to clarify the anti-vaccine effects associated with risperidone